S. Rosenfeld

509 total citations
14 papers, 344 citations indexed

About

S. Rosenfeld is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Rosenfeld has authored 14 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Rosenfeld's work include Glioma Diagnosis and Treatment (7 papers), Cancer Treatment and Pharmacology (4 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). S. Rosenfeld is often cited by papers focused on Glioma Diagnosis and Treatment (7 papers), Cancer Treatment and Pharmacology (4 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). S. Rosenfeld collaborates with scholars based in United States. S. Rosenfeld's co-authors include John M. Hoffman, Michael W. Hanson, Hetty Waskin, R. Edward Coleman, Linda Gray, T Schifter, Robert E. Coleman, Michael Glantz, S. Clifford Schold and Donald E. Macfarlane and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

S. Rosenfeld

12 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Rosenfeld United States	6	120	106	101	83	46	14	344
Dominic Kaddu‐Mulindwa Germany	8	58 0.5×	37 0.3×	76 0.8×	20 0.2×	38 0.8×	37	296
Arif Alam United Arab Emirates	9	114 0.9×	31 0.3×	162 1.6×	24 0.3×	19 0.4×	26	333
Martina Stiefel Germany	7	16 0.1×	88 0.8×	201 2.0×	56 0.7×	52 1.1×	11	306
Nimish Shah United Kingdom	10	44 0.4×	40 0.4×	85 0.8×	80 1.0×	11 0.2×	25	300
Lauris Gastaud France	9	33 0.3×	59 0.6×	95 0.9×	13 0.2×	53 1.2×	19	209
S. Toquet France	9	27 0.2×	18 0.2×	71 0.7×	43 0.5×	44 1.0×	16	315
Yusuke Kanemasa Japan	9	30 0.3×	49 0.5×	105 1.0×	10 0.1×	38 0.8×	30	291
Andrea Tedeschi Italy	9	31 0.3×	24 0.2×	47 0.5×	38 0.5×	25 0.5×	22	264
Robert Irby United States	11	48 0.4×	27 0.3×	26 0.3×	40 0.5×	22 0.5×	20	346
V. Rodriguez United States	8	42 0.3×	38 0.4×	44 0.4×	6 0.1×	111 2.4×	18	395

Countries citing papers authored by S. Rosenfeld

Since Specialization

Citations

This map shows the geographic impact of S. Rosenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Rosenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Rosenfeld more than expected).

Fields of papers citing papers by S. Rosenfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Rosenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Rosenfeld. The network helps show where S. Rosenfeld may publish in the future.

Co-authorship network of co-authors of S. Rosenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of S. Rosenfeld. A scholar is included among the top collaborators of S. Rosenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Rosenfeld. S. Rosenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Rosenfeld, S., et al.. (2025). Abstract P1-11-21: Dose Reduction Impacts Persistence on Abemaciclib: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database. Clinical Cancer Research. 31(12_Supplement). P1–11.

Chamberlain, Marc C., Jianwei Zhu, Jeffrey J. Raizer, et al.. (2011). Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab.. Journal of Clinical Oncology. 29(15_suppl). 2088–2088. 5 indexed citations

Drappatz, Jan, A. J. Brenner, S. Rosenfeld, et al.. (2010). ANG1005: Results of a phase I study in patients with recurrent malignant glioma.. Journal of Clinical Oncology. 28(15_suppl). 2009–2009. 12 indexed citations

Nabors, Burt, S. Rosenfeld, Marc C. Chamberlain, et al.. (2009). A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects. Journal of Clinical Oncology. 27(15_suppl). 2041–2041. 1 indexed citations

Castaigne, Jean‐Paul, Kelly Elian, S. Rosenfeld, et al.. (2008). 425 POSTER ANG1005: Preliminary clinical safety and tolerability in patients with recurrent malignant glioma. European Journal of Cancer Supplements. 6(12). 133–134. 1 indexed citations

Balmaceda, Casilda, Susan C. Pannullo, Michael B. Sisti, et al.. (2006). Treatment with temozolomide for malignant gliomas: Is rechallenge with alternative dosing regimens successful?. Journal of Clinical Oncology. 24(18_suppl). 11514–11514. 1 indexed citations

Aballéa, Samuel, J Chancellor, Maria Raikou, et al.. (2005). CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY. Value in Health. 8(6). A21–A21. 1 indexed citations

Rosenfeld, S.. (2005). Targeting nanomachines to treat malignant brain tumors. Nanomedicine Nanotechnology Biology and Medicine. 1(3). 264–264. 1 indexed citations

Newman, Arthur J., John B. Fiveash, S. Rosenfeld, et al.. (2004). A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 22(14_suppl). 1537–1537. 2 indexed citations

10.

Rosenfeld, S., et al.. (2002). Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient. Thrombosis and Haemostasis. 87(5). 925–926. 44 indexed citations

11.

Halperin, Edward C., S. Clifford Schold, Nicholas A. Vick, et al.. (1994). A phase III randomized prospective trial of external beam radiotherapy (ERT), mitomycin C (MITO), BCNU, and 6-mercaptopurine (6-MP) for the treatment of adults with anaplastic glioma of the brain. International Journal of Radiation Oncology*Biology*Physics. 30. 214–214. 1 indexed citations

12.

Hoffman, John M., Hetty Waskin, T Schifter, et al.. (1993). FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.. PubMed. 34(4). 567–75. 172 indexed citations

13.

Rosenfeld, S., John M. Hoffman, Robert E. Coleman, et al.. (1992). Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.. PubMed. 33(4). 532–6. 80 indexed citations

14.

Rosenfeld, S., et al.. (1960). Enhancement of Experimental Atherosclerosis by ACTH in the Dog.. Experimental Biology and Medicine. 103(1). 83–86. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact